docetaxel oral/ritonavir (ModraDoc006/r) / Modra Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
docetaxel oral/ritonavir (ModraDoc006/r) / Modra Pharma
NCT05242926: Absorption and Excretion of Oral Docetaxel

Withdrawn
1
0
Europe
ModraDoc006/r, oral docetaxel formulation
Modra Pharmaceuticals
Solid Tumor, Adult
04/18
06/18
NCT03147378: Food Effect Study of ModraDoc006 in Combination With Ritonavir

Completed
1
18
Europe
ModraDoc006/r, oral docetaxel formulation
Modra Pharmaceuticals, The Netherlands Cancer Institute
Solid Tumor, Adult
04/18
04/18
NCT03150368 / 2017-000347-41: Extended Use of ModraDoc006/r

Completed
1
17
Europe
ModraDoc006/r, oral docetaxel formulation
Modra Pharmaceuticals
Advanced Solid Tumours
05/18
05/19
NCT03136640 / 2016-005056-13: ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Completed
1
23
Europe
ModraDoc006/r, oral docetaxel formulation
Modra Pharmaceuticals, The Netherlands Cancer Institute
Castration-resistant Prostate Cancer
09/19
09/19
NCT05084456: Oral Docetaxel in Patients With Normal or Impaired Liver Function

Withdrawn
1
0
Europe
ModraDoc006/r, Oral docetaxel formulation
Modra Pharmaceuticals
Solid Tumor, Adult, Impaired Liver Function
02/20
04/20

Download Options